Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.43 |
| ▸ | USP2 | O75604 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 7/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27162660 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP2D6USP2CYP1A2ALDH1A1 | |
| SCHEMBL27162506 | 0.96 | ALDH1A1 (0.41) | CYP3A4CYP2D6USP2CYP1A2ALDH1A1 | |
| SCHEMBL30049837 | 0.96 | ALDH1A1 (0.41) | CYP3A4CYP2D6USP2CYP1A2ALDH1A1 | |
| SCHEMBL27162540 | 0.93 | CYP3A4 (0.47) | CYP3A4CYP2D6USP2CYP1A2ALDH1A1 | |
| SCHEMBL30049716 | 0.93 | CYP3A4 (0.47) | CYP3A4CYP2D6USP2CYP1A2ALDH1A1 | |
| SCHEMBL30051119 | 0.92 | ALDH1A1 (0.43) | CYP3A4CYP2D6USP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL27162256 | 0.92 | ALDH1A1 (0.43) | CYP3A4CYP2D6USP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL30049557 | 0.90 | ALDH1A1 (0.41) | CYP3A4CYP2D6USP2CYP1A2ALDH1A1 | |
| SCHEMBL27162302 | 0.90 | ALDH1A1 (0.41) | CYP3A4CYP2D6USP2CYP1A2ALDH1A1 | |
| SCHEMBL30050906 | 0.87 | CYP3A4 (0.47) | CYP3A4CYP2D6USP2CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4330248-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS | Acondicionamiento Tarrasense (ES) | 2024-03-06 | — | — | EP | claimed |
| WO-2022229405-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS | ACONDICIONAMIENTO TARRASENSE (ES) | 2022-11-03 | — | — | WO | claimed |
| US-20240254115-A1 | New Pyridine-Sulfonamide Derivatives as Sigma Ligands | ACONDICIONAMIENTO TARRASENSE (ES) | 2024-08-01 | — | — | US | disclosed |
| EP-4330248-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS | Acondicionamiento Tarrasense (ES) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022229405-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS | ACONDICIONAMIENTO TARRASENSE (ES) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254115-A1 | New Pyridine-Sulfonamide Derivatives as Sigma Ligands | SIGMAR1, TMEM97, OPRD1 | CYP3A4 497/4885CYP2D6 514/4885USP2 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.